Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 11 citing articles:

YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer
Ziyi Wang, Shijia Wang, Ziheng Jia, et al.
Cancer Letters (2023) Vol. 563, pp. 216184-216184
Closed Access | Times Cited: 28
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases
Christian Bailly, Xavier Thuru, Laurence Goossens, et al.
Biochemical Pharmacology (2023) Vol. 209, pp. 115445-115445
Open Access | Times Cited: 21
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets
Tatiana Vilela, Sofia Valente, Jorge Correia, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189144-189144
Open Access | Times Cited: 5
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Lin Chen, Yuqing Chao, Wenjing Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
Christina Bruß, Kerstin Kellner, Veruschka Albert, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2615-2615
Open Access | Times Cited: 10
Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3
Bernardo L. Rapoport, Helen C. Steel, Carol Benn, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy
Christina Bruß, Veruschka Albert, Stephan Seitz, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
Sofia Valente, Catarina Nascimento, Andreia Gameiro, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 384-384
Open Access | Times Cited: 3
The role of the BTLA–HVEM complex in the pathogenesis of breast cancer
Xue Hu
Breast Cancer (2024) Vol. 31, Iss. 3, pp. 358-370
Closed Access
Growth differentiation factor 15 is required for triple-negative breast cancer cell growth and chemoresistance
Yan‐Ling He, Xinyuan Zhang, Yunli Zhang, et al.
Anti-Cancer Drugs (2022)
Closed Access | Times Cited: 2
Page 1

Scroll to top